Resmed INC Form 4 insider transactions

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares on March 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Peter Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $227.71 per share on March 5, 2025, under a pre-arranged 10b5-1 trading plan.

Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed, executed stock options and sold shares on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $234.1 per share on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $238.98 per share on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $242.11 per share on February 5, 2025, under a pre-arranged 10b5-1 trading plan.

Michael J. Rider, Global General Counsel of ResMed Inc., sold 64 shares of common stock at $242.42 per share on February 3, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed Common Stock at a price of $234.04 per share on January 8, 2025, under a pre-arranged 10b5-1 trading plan.

Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock on January 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, sold 75 shares of common stock at $230.99 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of company stock at $244.23 per share on December 9, 2024, under a pre-arranged 10b5-1 trading plan.

ResMed director Peter C. Farrell sold 2,000 shares of common stock at $245.65 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, reported a gift of 173 shares and the sale of 74 shares under a pre-arranged trading plan.

ResMed CEO Michael Farrell engaged in share transfers and received stock options, according to a recent SEC filing.

ResMed director Peter C. Farrell exercised stock options and disposed of shares on November 25, 2024.

ResMed's Chief Product Officer, Justin Leong, sold 6,160 shares of company stock at an average price of $243.087.

ResMed director Ronald Taylor acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Desney Tan acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Richard Sulpizio acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Karen Drexler acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Jan De Witte acquired 1,083 shares of common stock through the vesting of restricted stock units.

Director John Hernandez of ResMed Inc. reports acquiring 1,083 shares of common stock and disposing of 4,045 shares, according to a recent SEC filing.

ResMed director Harjit Gill acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Christopher DelOrefice acquired 1,083 shares of common stock through the vesting of restricted stock units.

ResMed director Carol Burt acquired 1,083 shares of common stock and disposed of 2,851 shares held indirectly through a trust.

ResMed director Peter C. Farrell acquired 542 restricted stock units on November 20, 2024.

ResMed director Jan De Witte sold 796 shares of common stock at $248.81 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

ResMed director Peter C. Farrell disposed of 527.905 shares of common stock to cover tax obligations related to vesting restricted stock units.

ResMed director Harjit Gill disposed of 132.601 shares of common stock to cover tax obligations related to vesting restricted stock units.